INNO — Innocan Pharma Income Statement
0.000.00%
Last trade - 00:00- CA$47.87m
- CA$43.51m
- $29.44m
- 76
- 41
- 18
- 41
Annual income statement for Innocan Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.008 | 0.196 | 2.56 | 13.7 | 29.4 |
| Cost of Revenue | |||||
| Gross Profit | 0.003 | 0.121 | 2.11 | 12 | 26.2 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 4.73 | 7.68 | 8.82 | 17.5 | 30.7 |
| Operating Profit | -4.72 | -7.48 | -6.27 | -3.8 | -1.25 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9.95 | -10.1 | -3.89 | -4.03 | 0.919 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -9.95 | -10.1 | -3.89 | -4.25 | -0.262 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -9.95 | -10 | -3.76 | -4.7 | -1.83 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.95 | -10 | -3.76 | -4.7 | -1.83 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.061 | -0.045 | -0.015 | -0.018 | -0.007 |